Morning Briefing
Summaries of health policy coverage from major news organizations
New IV Antibiotic Combo For cUTI Being Reviewed; Benefits Of New Cancer Meds Unclear
Venatorx Pharmaceuticals, based in Malvern, Pennsylvania, today announced that the US Food and Drug Administration (FDA) has accepted for priority review its cefepime-taniborbactam antibiotic combination for treating complicated urinary tract infections (cUTIs). Cefepime-taniborbactam is an investigational intravenous (IV) beta-lactam/beta-lacatamase inhibitor antibiotic developed for adults with cUTI, including pyelonephritis. The drug has previously received FDA fast-track designation, and the FDA has set a target action date of February 22, 2024. (Schnirring, 8/15)
New cancer drugs are being launched at a rapid pace, before their long-term effectiveness for patients can be evaluated. Several years later, most of them still lack scientific evidence for actually increasing life expectancy or improving quality of life. (University of Gothenburg, 8/15)
The U.S. health regulator has approved expanding the use of Revance Therapeutics' Daxxify to treat a painful neck muscle condition, intensifying the anti-wrinkle injection's rivalry with AbbVie's Botox. The approval by the Food and Drug Administration helps Revance enter the $2.5 billion U.S. market for therapeutic neuromodulator, a method that directly acts on nerves, the company said on Monday. (Leo, 8/14)
A scientific journey decades in the making has found a new antibiotic strategy to defeat gram-negative bacteria like Salmonella, Pseudomonas and E. coli, the culprits in many urinary tract infections. (Duke University, 8/9)
